Your browser is no longer supported. Please, upgrade your browser.
Palatin Technologies, Inc.
Index- P/E- EPS (ttm)-0.15 Insider Own9.10% Shs Outstand238.23M Perf Week49.53%
Market Cap133.67M Forward P/E- EPS next Y-0.10 Insider Trans0.00% Shs Float221.26M Perf Month33.37%
Income-36.80M PEG- EPS next Q0.00 Inst Own8.90% Short Float3.46% Perf Quarter18.64%
Sales0.30M P/S445.56 EPS this Y-48.60% Inst Trans-9.57% Short Ratio2.18 Perf Half Y1.47%
Book/sh0.18 P/B3.10 EPS next Y36.40% ROA-49.90% Target Price2.33 Perf Year26.04%
Cash/sh0.22 P/C2.50 EPS next 5Y- ROE-65.90% 52W Range0.33 - 1.30 Perf YTD-17.49%
Dividend- P/FCF- EPS past 5Y15.50% ROI- 52W High-40.28% Beta0.99
Dividend %- Quick Ratio5.90 Sales past 5Y- Gross Margin31.90% 52W Low135.24% ATR0.04
Employees26 Current Ratio6.00 Sales Q/Q- Oper. Margin- RSI (14)87.16 Volatility16.88% 7.29%
OptionableNo Debt/Eq0.00 EPS Q/Q-79.10% Profit Margin- Rel Volume50.78 Prev Close0.56
ShortableYes LT Debt/Eq0.00 EarningsNov 15 BMO Payout- Avg Volume3.50M Price0.78
Recom1.30 SMA2089.51% SMA5082.68% SMA20039.36% Volume67,812,068 Change39.22%
Jun-05-15Reiterated Canaccord Genuity Buy $4 → $6
Jan-12-15Reiterated ROTH Capital Buy $6 → $4
May-23-12Initiated Noble Financial Buy
Jan-23-07Initiated Next Generation Buy $5
Nov-24-21 11:20AM  
Nov-15-21 07:30AM  
Nov-10-21 04:30PM  
Oct-22-21 07:30AM  
Sep-29-21 07:30AM  
Sep-27-21 07:30AM  
Sep-24-21 07:30AM  
Sep-15-21 07:30AM  
Sep-13-21 07:00AM  
Jul-22-21 05:28PM  
Jul-08-21 04:15PM  
Jun-29-21 07:30AM  
Jun-28-21 07:30AM  
Jun-10-21 07:30AM  
May-17-21 09:15AM  
May-14-21 07:30AM  
May-13-21 07:30AM  
May-04-21 07:30AM  
Apr-20-21 07:30AM  
Mar-11-21 08:17AM  
Mar-05-21 07:30AM  
Feb-17-21 09:15AM  
Feb-12-21 07:30AM  
Feb-11-21 09:59AM  
Feb-10-21 08:01AM  
Feb-05-21 09:47AM  
Feb-04-21 11:30AM  
Dec-22-20 01:17PM  
Dec-15-20 07:00AM  
Nov-29-20 12:13PM  
Nov-19-20 11:11AM  
Nov-17-20 09:15AM  
Nov-12-20 07:30AM  
Sep-28-20 09:00AM  
Sep-24-20 04:00PM  
Sep-10-20 05:47PM  
Aug-13-20 04:12PM  
Jul-14-20 01:19PM  
Jul-08-20 07:30AM  
Jun-29-20 07:30AM  
Jun-23-20 04:54PM  
Jun-05-20 03:14PM  
May-14-20 07:02PM  
May-13-20 03:01AM  
May-12-20 07:30AM  
Apr-30-20 07:30AM  
Mar-28-20 10:28AM  
Mar-03-20 12:56PM  
Feb-21-20 10:22AM  
Feb-19-20 07:30AM  
Feb-11-20 07:30AM  
Feb-06-20 07:30AM  
Jan-21-20 07:30AM  
Jan-16-20 08:36AM  
Dec-20-19 05:13PM  
Dec-11-19 11:43AM  
Dec-03-19 11:44PM  
Nov-13-19 07:30AM  
Nov-07-19 07:30AM  
Oct-31-19 11:53AM  
Oct-17-19 07:00AM  
Oct-16-19 07:00AM  
Oct-08-19 02:06PM  
Sep-17-19 05:41PM  
Sep-12-19 07:30AM  
Sep-11-19 12:00PM  
Aug-19-19 10:44AM  
Aug-16-19 10:42AM  
Aug-13-19 05:45PM  
Aug-06-19 09:30AM  
Jul-26-19 05:45PM  
Jul-19-19 05:45PM  
Jul-17-19 09:30AM  
Jul-12-19 12:51PM  
Jul-01-19 07:00AM  
Jun-25-19 03:49PM  
Jun-24-19 04:45PM  
Jun-21-19 05:41PM  
Jun-06-19 07:30AM  
May-20-19 03:48PM  
May-14-19 08:17AM  
May-10-19 01:23PM  
May-09-19 09:00AM  
May-03-19 04:30PM  
Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor (MCr) 1 agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and systemic PL8177, which has completed Phase I clinical trial for treating non-infectious uveitis and COVID-19. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, a dual NPR-A and NPR-C agonist to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was founded in 1986 and is based in Cranbury, New Jersey.